Your trusted source for investing success

Tag: US Food and Drug Administration

Looking for Cannabis Stocks?

Read our report to find market data, important news and stocks to watch!
 
What is Medical Device Security?

What is Medical Device Security?

The bigger problem is when these attacks are against healthcare companies carrying millions of patients personal information; the attacks can lead to postponed surgeries, leaking information or even shutting down entire computer networks in hospitals.

Motus Goes Public on the NASDAQ

Motus Goes Public on the NASDAQ

Medical device company, Motus (NASDAQ:MOTS), made the switch from private to public today on the NASDAQ Capital market, but Renaissance Capital stated the company’s initial public offering (IPO) on the low side of $5 instead of a high of $7.

Elite Pharmaceuticals and SunGen Pharma File ANDA

Elite Pharmaceuticals (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it has filed an Abbreviated New Drug Application with the US Food and Drug Administration (FDA) for a generic version of an immediate release CNS stimulant.

As quoted in the press release:
“The filing of

Novartis receives FDA approval for Cosentyx label update to include moderate-to-severe scalp psoriasis

Novartis (VTX: NOVN) announced that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis. The updated label includes Cosentyx data in moderate-to-severe scalp psoriasis – one of the difficult-to-treat forms of the disease, which

Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation

Abeona Therapeutics (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced that the US Food and Drug Administration has granted the Regenerative Medicine Advanced Therapy designation to EB-101, the Company’s gene-corrected autologous cell therapy product for patients with recessive

Novartis Advanced Accelerator Applications Receives FDA Approval for Lutathera

Novartis (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration approval of its new drug application for Lutathera® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors, in

Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA

Advanced Accelerator Applications (NASDAQ:AAAP) a Novartis company and leader in nuclear medicine theragnostics, today announced that  it has received US Food and Drug Administration approval of its new drug application (NDA) for LUTATHERA® (lutetium Lu 177 dotatate) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.

As quoted in the press release:
NETs

FDA has approved Faron’s Traumakine® IND

Faron Pharmaceuticals (AIM: FARN) a clinical stage biopharmaceutical company, announced the US Food and Drug Administration has approved the Investigational New Drug Application for Traumakine, the Company’s wholly-owned product for the treatment of Acute Respiratory Distress Syndrome, which is part of the regulatory process towards BLA submission.

As quoted in the

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Cannabis Weekly Round-Up: Branding Could Become the Key Metric for Shareholders

URL: https://investingnews.com/daily/resource-investing/agriculture-investing/cannabis-investing/cannabis-weekly-roundup/